Discover all specialist articles in the acute coronary syndrome section

icon
Academy
A diverse collection of educational videos on a wide range of medical topics.
icon
Complete archive
Search our extensive archive and use the personalized filter function to find exactly the issue of the magazine you need.
icon
Dossiers
We have grouped articles from across the Swiss Health Web universe into themed folders.
icon
e-Paper
Benefit from our e-papers and enjoy the convenience of reading our journals on the device of your choice - whenever and wherever you want.
icon
EbM-Guidelines
The evidence-based EbM guidelines offer you practice-oriented instructions for a wide range of clinical pictures.
icon
Tools
Our range of working tools is carefully curated to support you with comprehensive resources to make your everyday medical life easier.
Barbara Pitta Gros, et. al.
Published on 01.09.2021
Barbara Pitta Gros
+2

The authors present a case of acute coronary syndrome caused by a covered rupture of the aorta compressing the left main coronary artery. The cause of the rupture was later revealed to be a giant cell aortitis in a patient who had no other symptoms and was not known for giant cell arteritis.

Jasper Boeddinghaus, et. al.
Published on 17.12.2019
Jasper Boeddinghaus
+7

In the evaluation of patients with symptoms suggestive of acute coronary syndrome (ACS), biomarker testing is best established for cardiac troponins (cTn). As a heart specific marker of myocardial injury, cTn complements the clinical assessment and the 12-lead electrocardiogram in the diagnosis of ACS.

 

With the introduction of high-sensitivity cardiac troponin (hs-cTn) assays, reliable measurement of cTn concentrations in the normal range became possible, which increased diagnostic accuracy for myocardial infarction (MI) at presentation. Recent studies showed that single measurements of hs-cTn concentrations allow to predict MI with high probability and to identify high-risk patients who may benefit from early rhythm monitoring and/or invasive management. Novel hs-cTn assays are continuously developed and clinically validated. Their clinical use embedded in diagnostic strategies facilitates the early triage of patients presenting with chest pain to the emergency department. Accordingly, the European Society of Cardiology recommends such strategies with a class I recommendation. Newer evidence suggest that the clinical use of these strategies is also safe in the elderly, a patient population with high prevalence of ACS.

CVM
CVM
Issue 2024/03
CVM
CVM
Issue 2024/02
CVM
CVM
Issue 2024/01
CVM
CVM
Issue 2023/06
CVM
CVM
Issue 2023/05
Coverbild nicht verfügbar
CVM
Issue 2023/04
Coverbild nicht verfügbar
CVM
Issue 2023/03
Coverbild nicht verfügbar
CVM
Issue 2023/02
Coverbild nicht verfügbar
CVM
Issue 2023/01
Coverbild nicht verfügbar
CVM
Issue 2022/06